Endotoxin Testing for Extracellular Vesicles (EVs): Matrix Interference, Sample Preparation, and Method Suitability

Introduction: Why Endotoxin Testing Matters for Extracellular Vesicles

Extracellular vesicles (EVs) have attracted growing interest in biomedical research and therapeutic development. These membrane-enclosed particles are released by cells and can carry proteins, lipids, nucleic acids, and other biologically relevant components. Exosomes are a commonly discussed EV subtype, although the terms extracellular vesicle and exosome are not interchangeable in every scientific context.

Researchers are investigating EVs for applications ranging from drug delivery and regenerative medicine to diagnostics and cell-free therapeutic approaches. As these technologies advance, analytical methods capable of characterizing product quality and identifying potential contaminants become increasingly important.

One critical consideration is bacterial endotoxin contamination.

Endotoxins are lipopolysaccharides (LPS) associated with the outer membrane of Gram-negative bacteria. They can enter biological manufacturing workflows through water, raw materials, cell culture components, equipment, and other process-related sources. Their presence may be particularly consequential when an EV preparation is intended for administration to humans or animals.

However, endotoxin testing for EV preparations is not always straightforward. EV samples may contain residual proteins, culture-medium components, serum-derived materials, polymers, or other substances that affect analytical performance. In addition, the relationship between endotoxin and vesicles may complicate sample preparation and interpretation.

A negative assay result does not automatically establish that an EV preparation is free of endotoxin. The laboratory must also demonstrate that the selected method can detect endotoxin reliably in the actual sample matrix.

This article examines the main challenges of endotoxin testing for extracellular vesicles, including contamination sources, analytical method selection, matrix interference, sample preparation, positive product control (PPC) recovery, and ongoing quality control.

1. Understanding Endotoxin Risks in EV Manufacturing

Extracellular vesicles can be produced from different biological sources, including mammalian cell cultures, stem cells, immune cells, and other cell types. Manufacturing workflows may involve cell expansion, conditioned-medium collection, clarification, concentration, purification, formulation, and storage.

Each stage can introduce or concentrate potential contaminants.

1.1 Cell culture media and supplements

Culture media and supplements are important potential sources of process-related contamination.

Materials such as serum, growth supplements, recombinant proteins, and other additives should be assessed according to their origin, specifications, and intended use. Materials of biological origin may present additional variability, while water, handling, and storage conditions can also influence contamination risk.

Even when a supplier provides endotoxin-related specifications, those specifications do not eliminate the need for appropriate incoming-material controls and process risk assessment.

Where possible, manufacturers should establish suitable material qualification procedures and investigate unexpected changes in endotoxin results.

1.2 Water, equipment, and process-contact materials

Water is used throughout many EV manufacturing and analytical workflows. Process-contact equipment, tubing, containers, and filtration assemblies may also contribute to contamination if they are not appropriately controlled.

A contamination event can occur during production or during sample preparation in the analytical laboratory. The two situations require different corrective actions, making it important to distinguish genuine process contamination from contamination introduced during testing.

Laboratories should use water and consumables appropriate for bacterial endotoxins testing and follow qualified procedures for cleaning, handling, and storage.

FireGene provides endotoxin assay water for relevant testing workflows. Laboratories should confirm the current product specifications and use the material according to the applicable procedure.

1.3 Purification does not automatically establish endotoxin absence

EV manufacturing may involve centrifugation, filtration, size-based separation, chromatography, or other purification techniques.

These processes are designed for particular separation objectives. Their effectiveness against endotoxin depends on the process design, material properties, and operating conditions.

Endotoxin and EVs can have different physical and chemical properties, but their behavior in a complex preparation cannot be predicted reliably from a single property alone. Endotoxin may remain in the preparation, associate with other components, or be distributed differently depending on the system.

Consequently, a purification step should not be assumed to remove endotoxin unless that performance has been demonstrated using appropriate evidence.

1.4 Formulation and final handling

After purification, EV preparations may be concentrated or formulated with stabilizers and other excipients.

Formulation components can influence the analytical behavior of the final product. In addition, contamination may be introduced during transfer, filling, or storage.

Endotoxin control should therefore cover the manufacturing process and final product rather than relying exclusively on an intermediate purification result.

2. Why EV Samples Can Be Difficult to Test

The analytical challenge is not limited to the possibility of endotoxin contamination. The sample itself may influence the assay.

An EV preparation is a complex biological matrix. Depending on its source and manufacturing process, it may contain vesicles, soluble proteins, residual medium components, lipids, nucleic acids, and other materials.

The composition can vary substantially between products, so method suitability must be assessed for the specific preparation.

2.1 Matrix inhibition

Inhibition occurs when sample components suppress the expected response of an endotoxin detection method.

Potential contributing factors include:

• Sample pH or ionic conditions that are unsuitable for the assay.

• Residual culture-medium components or formulation excipients.

• High concentrations of proteins or other matrix constituents.

• Interactions that change endotoxin availability to the detection system.

• Sample preparation conditions that affect assay performance.

Inhibition can produce an artificially low result. This is particularly concerning when the laboratory is assessing whether a product meets an endotoxin acceptance criterion.

A low numerical value is not sufficient evidence of reliable detection if the assay has not demonstrated acceptable performance in the sample matrix.

2.2 Matrix enhancement

Enhancement occurs when the sample produces a response greater than expected under the established test conditions.

Potential causes include matrix-related effects, contamination introduced during preparation, and other analytical variables.

An enhanced response can complicate result interpretation and trigger unnecessary investigations if the cause is not understood.

However, laboratories should not automatically attribute an elevated result to matrix interference. Genuine contamination must remain part of the investigation.

2.3 Endotoxin and vesicle interactions

EV preparations introduce an additional consideration: endotoxin may interact with biological components in ways that affect its distribution or detection.

For example, endotoxin can associate with certain proteins, lipids, and other structures. Whether such interactions occur, and how they influence assay recovery, depends on the particular preparation and conditions.

It would be inappropriate to assume that all endotoxin binds to EVs or that every EV preparation behaves identically. Instead, the laboratory should evaluate whether the product matrix affects recovery under the intended analytical conditions.

2.4 Optical and reagent-related effects

Photometric endotoxin methods measure changes in turbidity or color development over time. Depending on the assay format, sample color, turbidity, or other optical properties may affect measurements.

The presence of particles does not automatically invalidate a photometric assay. The relevant question is whether the sample affects analytical performance under the selected procedure.

For this reason, method suitability should be supported by experimental data rather than by the appearance of the sample alone.

3. Selecting an Appropriate Endotoxin Testing Method

The appropriate assay depends on the product, the applicable regulatory and compendial requirements, the analytical objective, and the evidence available to demonstrate method suitability.

Common approaches include gel-clot and photometric bacterial endotoxins tests using suitable TAL/LAL reagents. Recombinant reagent methods may also be appropriate when their use is supported by the applicable requirements and product-specific suitability data.

No single assay format should be assumed to be universally suitable for all EV preparations.

3.1 Gel-clot testing

Gel-clot methods use a visible gel formation endpoint under specified reaction conditions.

Potential advantages include a relatively straightforward endpoint and limited reliance on optical instrumentation. However, the method has its own sensitivity, dilution, handling, and interpretation requirements.

When considering gel-clot testing for an EV preparation, the laboratory should evaluate whether the matrix supports acceptable detection at a suitable dilution and whether the procedure meets the intended analytical purpose.

FireGene's gel-clot endotoxin test kit is one option laboratories may consider when evaluating a suitable TAL-based workflow.

3.2 Kinetic chromogenic testing

Kinetic chromogenic assays measure color development over time. Within the established analytical range, the reaction rate can be related to endotoxin concentration.

This approach can support quantitative testing and trend analysis, provided the assay performs appropriately in the sample matrix.

For EV preparations, laboratories should consider whether residual matrix components affect color development, reaction kinetics, or measurement consistency.

The analytical range, calibration performance, control results, and PPC recovery should be evaluated under the intended testing conditions.

FireGene offers a kinetic chromogenic endotoxin test kit for laboratories assessing quantitative TAL-based endotoxin testing workflows.

3.3 Recombinant reagent methods

Recombinant endotoxin detection methods offer alternatives to traditional animal-derived lysate reagents. Their use may be considered as part of an appropriate analytical strategy, subject to applicable requirements and demonstrated suitability.

The choice of method should account for the product matrix, the intended use of the result, the supplier's technical documentation, and the applicable regulatory framework.

The FDA's March 2026 Pyrogen and Endotoxins Testing: Questions and Answers, Edition 2, provides relevant guidance on bacterial endotoxins testing and recombinant reagents.

Laboratories should review current official guidance and applicable compendial requirements before implementing or changing a method.

4. Method Suitability: Demonstrating Reliable Detection

Method suitability testing evaluates whether the selected procedure can detect endotoxin reliably in the presence of the product matrix.

For EV preparations, this is particularly important because different cell sources, culture conditions, purification processes, and formulations may produce samples with different analytical characteristics.

4.1 Positive product control recovery

A positive product control (PPC) is prepared by adding a known quantity of endotoxin to the sample under the prescribed test conditions.

The measured response is compared with the expected response to assess whether the matrix interferes with detection.

For methods governed by USP General Chapter <85>, the applicable PPC recovery criteria and procedure should be followed. A commonly used recovery range is 50%–200%, subject to the governing method and relevant requirements.

Recovery below the accepted range may indicate inhibition. Recovery above the accepted range may indicate enhancement or another analytical problem.

A satisfactory PPC result provides evidence that the assay can detect the added endotoxin under the tested conditions. It does not, by itself, prove that every aspect of the EV product is free from contamination or that all potential analytical limitations have been resolved.

4.2 Test the actual product matrix

Method suitability should be assessed using the actual product or a scientifically justified representative matrix under the intended testing conditions.

Important variables may include:

• EV source and product identity.

• Culture and purification process.

• Formulation and excipient composition.

• Sample concentration and preparation procedure.

• Reagent system and assay sensitivity.

• Dilution and relevant reaction conditions.

• Positive and negative control performance.

• PPC recovery and applicable acceptance criteria.

The study should be designed according to the product's characteristics and the requirements governing the intended test.

4.3 Establish a justified dilution strategy

Dilution may reduce the concentration of interfering matrix components. However, it also reduces the endotoxin concentration presented to the assay.

The laboratory should identify conditions that provide acceptable recovery while maintaining the ability to detect endotoxin at the required level.

The maximum valid dilution (MVD), where applicable under the governing framework, should be calculated using the appropriate endotoxin limit, sample concentration, and assay sensitivity.

Dilution should not be used to conceal interference or to obtain an apparently acceptable result without evidence that the procedure remains suitable.

4.4 Reassess suitability after meaningful changes

A method that performs acceptably for one EV preparation may not perform equally well for another.

Changes in cell source, culture medium, purification, concentration, formulation, or sample preparation can alter matrix characteristics.

A documented change-control process should determine whether existing suitability data remain adequate or whether additional testing is required.

5. Sample Preparation: Balancing Recovery and Product Integrity

Sample preparation is a critical part of endotoxin testing for EVs because it can influence both analytical performance and the characteristics of the material being tested.

The preparation strategy should support reliable endotoxin detection without introducing avoidable contamination or unvalidated changes to the sample.

5.1 Standardize sample handling

Laboratories should define the relevant sample preparation steps in an approved procedure.

These may include mixing, dilution, transfer, timing, storage, and other operations required by the assay.

The exact procedure should be based on the product's characteristics and the applicable method. Conditions should not be changed casually when a sample produces unexpected results.

5.2 Avoid unvalidated pretreatment

Heat treatment, extreme pH adjustment, detergents, enzymes, or other pretreatment approaches may alter the sample matrix. Depending on the system, they may also change endotoxin availability or the behavior of the detection assay.

For EV preparations, some treatments could additionally affect vesicle integrity or other product attributes.

A pretreatment that improves assay recovery is not automatically acceptable. It must be shown to be appropriate for the intended analytical purpose and consistent with the relevant quality requirements.

5.3 Use suitable water and consumables

Water, pipette tips, tubes, plates, and other sample-contact materials should be appropriate for bacterial endotoxins testing.

Contamination introduced during preparation can produce misleading results, while unsuitable materials may contribute to variability.

FireGene's endotoxin assay water and available endotoxin assay reagents and kits may be considered when establishing a suitable testing workflow. Laboratories should verify current specifications and ensure compatibility with their procedures.

5.4 Evaluate storage and hold time

Sample storage conditions and hold times should be established using appropriate evidence.

Changes during storage may affect sample characteristics or the measured recovery of endotoxin. The effect will depend on the specific preparation and conditions.

Where relevant, laboratories should evaluate whether the chosen storage and hold-time conditions maintain acceptable method performance.

6. Interpreting Results and Investigating Unexpected Findings

A reliable endotoxin testing program requires more than obtaining a numerical result. Laboratories need a clear framework for determining whether the result is valid, whether controls performed acceptably, and whether further investigation is necessary.

6.1 Low results with unacceptable PPC recovery

A low result accompanied by poor PPC recovery should raise concern about possible inhibition.

The laboratory should review the sample preparation procedure, dilution, reagent performance, control results, and other relevant conditions.

The result should not be treated as reliable evidence of low endotoxin content until the analytical issue has been appropriately addressed.

6.2 High results with acceptable controls

An elevated result with acceptable controls may represent genuine endotoxin contamination. The laboratory should investigate the result in accordance with its approved procedures.

Potential investigation areas include process materials, water, equipment, consumables, sample handling, and recent manufacturing changes.

Acceptable assay controls demonstrate that the run met the relevant control criteria; they do not establish that the product itself is free of contamination.

6.3 Inconsistent results between batches

Differences between EV batches may reflect changes in the product matrix, manufacturing process, sample handling, or analytical performance.

Trend analysis can help identify whether variability is associated with a particular process step, raw material, reagent lot, analyst, or testing condition.

A structured investigation should examine the evidence before assigning a cause.

6.4 Unexpectedly negative results after dilution

A negative result after extensive dilution may indicate low endotoxin content, but it may also reflect inadequate detection capability if the dilution is excessive.

The laboratory should verify the MVD calculation where applicable, confirm the method's sensitivity, and demonstrate suitability at the selected dilution.

The result must be interpreted within the established limits of the method.

7. Integrating Endotoxin Testing Into EV Quality Control

For EV products in development, endotoxin testing should be considered alongside other product-characterization and quality-control activities.

The specific testing strategy depends on the stage of development, the intended use, the applicable regulatory framework, and the product's risk profile.

7.1 Control contamination throughout manufacturing

Testing only the final preparation may not provide enough information to identify where contamination entered the process.

Where justified, process monitoring can help identify potential sources and evaluate the effectiveness of control measures.

Relevant areas may include water, raw materials, culture components, equipment, purification operations, and final formulation.

The sampling strategy should be risk-based and appropriate to the manufacturing process.

7.2 Monitor analytical trends

Longitudinal data can help identify gradual changes in endotoxin levels or assay performance.

Useful indicators may include:

• Changes in endotoxin results across batches.

• Repeated PPC recovery failures.

• Increased variability between replicate measurements.

• Differences associated with reagent lots or analytical instruments.

• Changes following a process or formulation modification.

• Recurrent contamination associated with particular materials.

Trend analysis should support, not replace, established specifications and investigation procedures.

7.3 Maintain traceable documentation

A defensible testing program should document the selected method, rationale, sample preparation, controls, dilution calculations, suitability studies, results, deviations, and investigations.

For products in development, documentation should also distinguish exploratory research measurements from results intended to support formal quality decisions.

This distinction is important because EV products may be at different stages of characterization and manufacturing development, and their applicable requirements may differ.

8. Regulatory and Compendial Considerations

The regulatory expectations for EV-based products depend on their intended use, product classification, development stage, and jurisdiction.

A research-use EV preparation should not automatically be treated as equivalent to a clinical therapeutic product. Similarly, a generic endotoxin limit should not be applied to every EV preparation without considering the relevant product-specific requirements.

USP General Chapter <85>, Bacterial Endotoxins Test, provides a widely used framework for applicable endotoxin testing procedures. USP General Chapter <86>, Bacterial Endotoxins Test Using Recombinant Reagents, addresses recombinant reagent-based approaches. Laboratories should consult the current official editions and confirm applicability to their products and procedures.

The FDA's current Pyrogen and Endotoxins Testing: Questions and Answers guidance is another important reference when developing or updating an endotoxin testing strategy.

For EV-based therapeutic products, manufacturers should confirm the applicable regulatory expectations rather than assuming that a general research protocol or a method validated for another biological product is sufficient.

9. A Practical Checklist for EV Endotoxin Testing

Before implementing or revising an endotoxin testing procedure for extracellular vesicles, laboratories can review the following areas.

Product and process understanding

• Identify the EV source and relevant product characteristics.

• Review culture media, supplements, water, and process-contact materials.

• Assess potential contamination sources throughout manufacturing.

• Establish the applicable product-specific endotoxin requirements.

Analytical method

• Select a suitable assay format and reagent system.

• Review the assay sensitivity and analytical range.

• Evaluate relevant optical or matrix-related effects.

• Confirm that the method is appropriate for the intended purpose.

Method suitability

• Test the actual product matrix under intended conditions.

• Evaluate PPC recovery according to the applicable procedure.

• Investigate inhibition or enhancement.

• Establish a justified dilution strategy and respect the applicable MVD.

• Reassess suitability after meaningful product or method changes.

Sample preparation

• Use appropriate water and consumables.

• Standardize handling, dilution, and timing.

• Avoid unvalidated pretreatment.

• Establish suitable storage and hold-time conditions.

Ongoing quality control

• Review controls and analytical trends.

• Investigate unexpected results and recurring deviations.

• Maintain traceable records.

• Align the testing strategy with current product-specific requirements.

Conclusion: Reliable EV Endotoxin Testing Starts With Demonstrated Method Suitability

Extracellular vesicles and exosome-based products present a growing area of biomedical research and therapeutic development. Their complex biological composition makes appropriate analytical controls particularly important.

Endotoxin testing can be affected by sample matrix characteristics, endotoxin interactions, dilution, sample preparation, and other analytical variables. A negative result alone cannot establish that the method performed reliably.

A robust approach combines appropriate method selection, product-specific suitability testing, acceptable PPC recovery, justified dilution, contamination prevention, and ongoing review of analytical data.

For laboratories developing EV products, these practices can help distinguish genuine product findings from analytical interference and support more consistent quality-control decisions.

FireGene provides endotoxin testing reagents and supporting products for laboratories evaluating appropriate testing workflows. Explore the FireGene endotoxin assay reagent collection to learn more about available solutions.

Important note: This article is intended for scientific and educational purposes. It does not establish a universal endotoxin limit or validated method for all extracellular vesicle products. Testing procedures, acceptance criteria, and regulatory requirements should be determined according to the specific product, intended use, applicable compendial standards, and validated laboratory procedures.

References

1. U.S. Food and Drug Administration. Pyrogen and Endotoxins Testing: Questions and Answers — Guidance for Industry, Edition 2. March 2026.

2. United States Pharmacopeia. General Chapter <85>, Bacterial Endotoxins Test. Consult the current official edition.

3. United States Pharmacopeia. General Chapter <86>, Bacterial Endotoxins Test Using Recombinant Reagents. Consult the current official edition and applicable implementation requirements.

4. Welsh, J. A., et al. “MISEV2023: From basic to advanced approaches.” Journal of Extracellular Vesicles. 2024. Consult the publication for current recommendations on extracellular vesicle terminology and characterization.